Topic Listing for Telik

Accounting Tax Considerations Accuracy Fair Value Estimates
Action Without Meeting Adjustments
Administration Adopted Stockholder Rights Plan Discourage Delay Prevent Merger
Adoption Sfas 123 Akt Kinase
Amendment Amendments
Annual Bonus Awards Annual Bonus Determinations
Annual Meetings Appendix
Approval Amendment 2000 Non-employee Directors Stock Option Plan Assist-1 Trial
Assist-2 Trial Assist-3 Trial
Attendance Annual Eeting Attendance Annual Meeting
Audit Committee Aurora Kinase
Aurora Kinase Inhibitor Authority
Available Information Award Mix
B5-1 Trading Plans Base Salary
Basic Diluted Net Loss Per Share Basis Presentation Summary Significant Accounting Policies
Been Future Subject Securities Class Action Lawsuits Shareholder Been Named Defendant Several Purported Securities Class Action
Believe Ability Compete Depends Part Proprietary Trap Technology Benchmarking
Beneficial Ownership Reporting Compliance Beneficial Stockholders
Benefits Biological Hazardous Materials Manner Causes Injury Liable Damages
Board Directors Recommends Vote Proposal Budget Constraints Force Delay Efforts Develop Certain Product
Business Strategy Cancer
Capital Leases Equipment Loans Capital Leases Loans
Cash Equivalents Investments Cash Equivalents Short-term Investments
Cash Equivalents Short-term Long-term Investments Certain Related-person Transactions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Transactions Certification
Certifications Change Control Severance Benefit Plan
Changes Internal Control Over Financial Reporting Chief Executive Officer Compensation
Clawback Executive Officer Bonuses Clinical Product Development
Clinical Product Development Programs Clinical Status
Code Ethics Collaborative Relationships
Committee Interaction Management Committee Membership Meetings
Committee Process Committees
Common Stock 001 Par Value Per Share Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Processes Procedures
Compensation Committee Report Compensation Directors
Compensation Discussion Analysis Compensation Mix
Compensation Objectives Compensation Philosophy
Compensation Positioning Competition
Competitors Develop Market Products Effective Product Candidates Obtain Composition
Comprehensive Income Loss Comprehensive Loss
Computershare Trust Conference Call Webcast
Consent Independent Registered Public Accounting Firm Contact
Contingencies Controls Procedures
Corporate Performance Ceo Compensation Corporate Seal
Corporation Costs Associated Exit Disposal Activities
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies Significant Judgments Estimates
Current Credit Financial Market Conditions Impact Ability Find Deferred Compensation
Delaware Departure Directors Certain Officers Election Appointment Compensatory
Director Compensation Table Directors
Directors Continuing Office Until 2006 Annual Meeting Directors Continuing Office Until 2007 Annual Meeting
Directors Continuing Office Until 2008 Annual Meeting Directors Continuing Office Until 2009 Annual Meeting
Directors Continuing Office Until 2010 Annual Meeting Directors Continuing Office Until 2011 Annual Meeting
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Disclosure Regarding Forward-looking Statements Dividends
Djustments Hanges Tock Dna Methyltransferase Inhibitor
Documents Incorporated Reference Duration Amendment Termination
Eetings Eetings Inutes
Effect Certain Corporate Events Efinitions
Election Directors Electronic Delivery Stockholder Communications
Elements Teliks Named Executive Officer Compensation Eligibility
Employee Stock Plans Employee Stock Purchase Plan
Employee Stock-based Compensation Employees
Employees Age Individual Group Termination Employees Age Older Group Termination
Employees Age Older Individual Termination Employment Severance Change Control Agreements
End Option Values Entry Material Definitive Agreement
Eports Equity Awards
Equity Compensation Plan Information Equity Grant Practices
Equity Incentive Plan Ermination Uspension Lan
Esponsibilities Estimates
Evaluation Disclosure Controls Procedures Evaluation Disclosure Controls Procedures Changes Internal Control Over
Evel Ligible Mployees Exact Name Registrant Specified Charter
Except Per Share Amounts Executive Compensation
Executive Compensation Philosophy Objectives Executive Officer Bonus Plan
Executive Officers Exhibits
External Advisors Fair Value Financial Instruments
Fair Value Measurements Fda Converts Telcyta Full Clinical Hold Partial
Fda Removes Partial Hold Telcyta Clinical Development Federal Income Tax Information
Ffective Ate Lan Financial Guidance
Financial Statements Exhibits Financial Statements Supplementary Data
Fixing Record Dates Follow-on Public Offering
Follow-on Public Offerings Form 10-k
Form 10-q Former Name Address Changed Since Last Report
General General Administrative Expenses
General Information Shares Voted Via Internet Telephone General Release Not Extend Claims Creditor Know Suspect
Governance Executive Compensation Program Grants Plan-based Awards 2006
Grants Plan-based Awards 2007 Grants Plan-based Awards 2008
Gst Inhibitor Gst Program
Guidance Hange Ontrol Everance Enefit Lan
Hares Ubject Lan Held 2006
History Net Losses Expect Continue Least Several Never History Net Losses Expect Continue Next Several Never
Hoffmann-la Roche Hoice
Hospital Special Surgery Householding Proxy Materials
Igf-1 Receptor Inhibitor Ignatures
Immediate Release Impairment Long-lived Assets
Implemented Anti-takeover Provisions Discourage Prevent Takeover Even Acquisition Income Taxes
Indemnification Directors Executive Officers Other Employees Agents Independence Board Directors Committees
Independent Registered Public Accounting Firm Fee Information Index
Index Exhibits Inherent Limitations Effectiveness Controls
Interest Income Expense Internal Revenue Code
Investment Substantial Cash Balance Investments Marketable Debt Securities Iscellaneous
Iscretionary Rants Key Personnel
Ligibility Limitation Deduction Compensation Paid Certain Executive Officers
Loans Officers Long Term Debt
Long Term Debt Commitments Long-term Incentive Compensation
Management Managements Report Internal Control Over Financial Reporting
Manufacturing Market Common Stock
Market Registrants Common Equity Related Stockholder Matters Issuer Material Modification Rights Security Holders
Mcp-1 Antagonist C243 -small Molecule Autoimmune Inflammatory Disorders Mcp-1 Antagonists C243 -small Molecule Autoimmune Inflammatory Disorders
Mcp-1 Antagonists C243 -small Molecules Autoimmune Inflammatory Disorders Mcp-1 Antagonists Cancer Inflammatory Diseases
Meetings Meetings Board Directors Committees
Meetings Minutes Mendment Lan Ptions
Mount Sinai School Medicine Name Person Filing Proxy Statement Other Registrant
Named Executive Officer Compensation Nasdaq Stock Listing Compliance Status
Nature Operations Basis Presentation Need Additional Capital
Need Implement Additional Finance Accounting Systems Procedures Controls Net Loss Per Common Share
Net Loss Per Share New Accounting Pronouncements
New Potential Accounting Pronouncements Impact Future Financial Position Nominating Committee
Nominee Election Three-year Term Expiring 2012 Annual Meeting Nominees Election Three-year Term Expiring 2008 Annual Meeting
Nominees Election Three-year Term Expiring 2009 Annual Meeting Nominees Election Three-year Term Expiring 2010 Annual Meeting
Nominees Election Three-year Term Expiring 2011 Annual Meeting Non-employee Directors Stock Option Plan
Not Applicable Not Find Collaborators Product Candidates Reduce Delay Rate
Not Obtain Regulatory Approval Market Products United States Not Progress Programs Anticipated Stock Price Decrease
Notes Financial Statements Notes Payable
Notice Annual Meeting Stockholders Held 2005 Notice Annual Meeting Stockholders Held 2006
Notice Annual Meeting Stockholders Held 2007 Notice Annual Meeting Stockholders Held 2008
Notice Annual Meeting Stockholders Held 2009 Notices
Number 0-31265 Off-balance Sheet Arrangements
Officers Offices
Omposition Operating Leases
Operating Principles Processes Option Awards Vesting Schedule
Option Grants Last Organization
Other Assets Other Considerations
Other Events Other Matters
Other Securities Corporation Outstanding Equity Awards 2006 Year-end
Outstanding Equity Awards 2007 Year-end Outstanding Equity Awards 2008 Year-end
Ovenants Ompany Overview
Overview Teliks Named Executive Officer Compensation Palo Alto California 94304
Parg Poly Adp-ribose Glycohydrolase Inhibitor Part
Part Other Information Part Other Nformation
Patents Proprietary Information Peer Group
Perating Rinciples Rocesses Performance Graph
Performance Measurement Comparison Physicians Patients Not Accept Products Develop Ability Generate
Plan Polo-like Kinase Plk-1
Porter Drive Palo Alto 94304 Post-employment Obligations
Potential Payments Termination Change Control Table Power Attorney
Pre-clinical Drug Product Development Prepaids Other Current Assets
Principal Accountant Fees Services Pro Forma Information Sfas 123
Product Candidate Pipeline Product Candidates Outside Control Require Relinquish Important Rights
Product Candidates Research Development Clinical Trials Telcyta Telintra Product Development
Product Development Programs Product Liability Lawsuits Successfully Brought Against Incur Substantial
Product Programs Advance Need Hire Additional Scientific Management Properties
Property Property Equipment
Property Equipment Net Proteasome
Proxy Solicited Board Directors Annual Meeting Stockholders Held Proxy Voted Accordance Therewith
Ption Rovisions Purpose
Purpose Policy Quantitative Qualitative Disclosures Market Risk
Quorum Voting Raf Kinase Inhibitor
Raising Additional Capital Issuing Securities Through Collaboration Licensing Ransition Ate Elease
Ratification Selection Independent Registered Public Accounting Firm Receive Information Plan Benefits
Recent Accounting Pronouncements Recent Upcoming Milestones
Receptorbio Inc Reclassification
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 650 845-7700
Regulatory Considerations Related Party Transaction
Release Claims Remainder Page Intentionally Left Blank Signature Follows
Removal Report Audit Committee Board Directors
Report Compensation Committee Board Directors Report Independent Registered Public Accounting Firm
Reports Research Development
Research Development Expenses Research Discovery Programs
Reserved Shares Resignation Employment
Respectfully Submitted Members Compensation Committee Board Directors Responsibilities
Restricted Investments Restrictions Transfer
Restructuring Costs Restructuring Efforts Adverse Impact Current Employees Ability Retain
Restructuring Plan Restructuring Plans
Restructuring Program Results
Results 2006 Financial Guidance Results Operations Financial Condition
Revenue Recognition Revenues
Revocability Proxies Rganization
Risk Factors Roceeds Tock
Role Compensation Committee Role Teliks Compensation Committee
Sanwa Sanwa Kagaku Kenkyusho Ltd
Schedule Schedule 14a Information
Securities Act Means 1933 Amended Dministration Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Sfas 123
Share-based Compensation Expense Shares Registered Name
Shares Registered Name Broker Bank Shares Stock
Signature Page Follow Signature Pages Follow
Signatures Solicitation
Source Shares Common Stock Subject Plan Unissued Reacquired Special Meetings
Special Regarding Statements Expected Future Performance Sri International
State Other Jurisdiction Incorporation Statement Policy
Stock Based Compensation Stock Based Compensation Fas 123r
Stock Option Exercises 2006 Stock Option Exercises 2007
Stock Option Exercises 2008 Stock Option Grants Exercises
Stock Option Plan Stock Options
Stock Ownership Guidelines Stock Price Volatile Not Able Resell Shares Above
Stock Subject Directors Plan Stock-based Compensation
Stock-based Compensation Expense Stock-based Compensation Sfas 123r
Stockholder Communications Board Directors Stockholder Proposals
Stockholder Rights Plan Stockholders Equity
Stockholders Meetings Stockholders Record
Strategy Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Substantial Future Sales Common Stock Existing Stockholders Cause Summary Compensation
Summary Compensation Table Summary Teliks Named Executive Officer Compensation Program
Swiss Tropical Institute Table Contents
Tatement Tatement Olicy
Tax Considerations Telcyta Safety
Telcyta-tumor-activated Cancer Product Candidate Telik
Telik Announces 2005 Financial Results Telik Announces 2006 End Financial Results 2007 Guidance
Telik Announces 2007 Financial Results Telik Announces 2008 Financial Results
Telik Announces 2009 Financial Results Telik Announces Clinical Hold Telcyta Trials
Telik Announces Corporate Restructuring Telik Announces Financial Results 2005
Telik Announces Financial Results 2006 Telik Announces Financial Results 2007
Telik Announces Financial Results 2008 Telik Announces Proposed Public Offering Common Stock
Telik Announces Public Offering Common Stock Telik Announces Receipt Nasdaq Notice
Telik Inc Telik Reports Preliminary Results Assist-1 Assist-2 Assist-3 Phase
Telintra-bone Marrow Stimulant Tenure Duties Officers
Terms Employee Bonus Plan 2005 Terms Executive Officer Bonus Plan
Terms Options Title Class
Tlk58747-cytotoxic Small Molecule Tlk60404-aurora Kinase Vegfr2 Inhibitors
Toward Drug Development Pipeline Transactions Related Persons
Transfers Trap Technology
Trap Technology Discover New Pharmaceutical Products Ubs Purchase Rights Loan
Unable Create Sales Marketing Distribution Capabilities Enter Agreements Unable Raise Adequate Funds Future Not Able Continue
University Arizona Unless Contrary Direction Indicated Proxy Voted Proposal Specifically
Urpose Olicy Urposes
Ursuant Hange Ontrol Everance Enefits Lan Elik Uthority
Vacancies Valuation Assumptions
Vanderbilt-ingram Cancer Center Vascular Endothelial Growth Factor Receptor
Vote Favor Proposal Voting Rights Outstanding Shares
Voting Via Internet Telephone Washington 20549
Working Capital Constraints Force Delay Efforts Develop Certain Xhibit Ndex
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki